NCT06936813

Brief Summary

The PROMISE Survey was developed to systematically assess the real-world experiences, treatment preferences, side effects, and outcomes from both patients and physicians dealing with prolactinomas. The aim is to generate insights that can guide future clinical research and improve individualized care strategies.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
530

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 10, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 20, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

June 13, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2026

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2026

Completed
Last Updated

January 8, 2026

Status Verified

January 1, 2026

Enrollment Period

7 months

First QC Date

April 10, 2025

Last Update Submit

January 5, 2026

Conditions

ProlactinomaPituitary Tumor

Keywords

Survey

Outcome Measures

Primary Outcomes (1)

  • Generate hypotheses for future research

    Generate real-world patient-centered data to identify patterns in treatment outcomes, patient-reported challenges, and areas where additional clinical trials are needed to develop new hypothesis for future research

    6 months

Secondary Outcomes (7)

  • Collect data on patient characteristics

    6 months

  • Assess patient experiences with dopamine agonist (DA) therapy

    6 months

  • Evaluate patient experiences with surgical treatment

    6 months

  • Collect data on diagnostic pathways

    6 months

  • Evaluate patient-reported quality of life (QoL) and psychosocial impact

    6 months

  • +2 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Prolactinoma patients and physicians involved in the management of prolactinomas. Survey will be accessible globally via online patient communities, pituitary disorder organizations, physician networks, and in-clinic distribution.

You may qualify if:

  • Prolactinoma patients
  • Prolactinoma treating physicians including endocrinologists and neurosurgeons

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Basel

Basel, 4031, Switzerland

Location

MeSH Terms

Conditions

ProlactinomaPituitary Neoplasms

Condition Hierarchy (Ancestors)

AdenomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsEndocrine Gland NeoplasmsNeoplasms by SitePituitary DiseasesHypothalamic DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesEndocrine System DiseasesHypothalamic NeoplasmsSupratentorial NeoplasmsBrain NeoplasmsCentral Nervous System NeoplasmsNervous System Neoplasms

Study Officials

  • Cihan Atila

    University Hospital, Basel, Switzerland

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 10, 2025

First Posted

April 20, 2025

Study Start

June 13, 2025

Primary Completion

January 1, 2026

Study Completion

March 30, 2026

Last Updated

January 8, 2026

Record last verified: 2026-01

Locations

CH(1)